Skip to content
Rachel King, Interim CEO of the Biotechnology Innovation Organization (BIO), described the organization’s work and goals for 2023 at the Maryland Tech Council (MTC)’s […]
BIO’s Interim CEO discusses biotech policy, optimism with industry in Maryland Read More »
When the largest private insurance companies use their leverage to save on the cost of prescription drugs, they make it harder for patients to
Excluding drugs from coverage helps PBMs keep profits higher Read More »
In 2022 drug manufacturers actually charged less for their products and patients paid slightly more than the previous year—but the cost of prescription medicines
While net drug prices drop, patients pay more thanks to health plans and PBMs Read More »
The process of holding clinical trials and gaining FDA approval takes up much of the time and expense involved in drug development, which can
BIO aids global harmonization, helping speed cures to patients Read More »
Plans to put limits on the FDA’s Accelerated Approval pathway would reduce the number of new treatments hitting the market, with a particularly negative
Provisions in the Inflation Reduction Act (IRA) make it easier for people covered by Medicare Part D to pay for medicine, but continued government
CMS must flesh out plan to ease out-of-pocket drug costs, report says Read More »
The U.S. biotech sector is a vital economic engine in all 50 states, providing 2.1 million jobs and a $2.9 trillion impact on the
U.S. biotech is a major economic driver with a broad range, report says Read More »
While the drug pricing provisions of the Inflation Reduction Act (IRA) are expected to kill drug innovation and hamper development of new treatments, the
IRA climate provisions can benefit biotech—and the planet Read More »
The practice of making drug makers give rebates to payers encourages Medicare Part D insurers to steer patients away from generic drugs that cost
HHS probe: Insurer PBMs pocket rebates as patients, taxpayers pay more Read More »
Congress needs to ensure the smooth continuation of two federal programs that provide seed funding for small, innovative businesses, according to a host of
SBIR/STTR seed-funding programs running out of money – and Congress needs to act Read More »
